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Introduction
There is considerable and continuing public concern related to an increase in the use of opioid painkillers in 
the United Kingdom. There is also professional and governmental concern regarding misuse of prescription 
medicines and the number of  prescriptions of opioid analgesics. The backdrop are the serious public health 
concerns in the USA. This document sets out the issues and recommendations for action locally.
Opioids in Chronic non-malignant pain
Pain is the 5th vital sign and pain relief can be viewed as a basic human right.  Opioids play a very important 
role in acute pain where there is a close relationship between pain and tissue damage. Examples of opioid use 
would be in Emergency Departments after trauma or following surgery.  They are frequently considered the 
“Gold Standard” for such acute pain treatment. 
In addition, opioids play an important role in the management of cancer pain and in the short to intermediate 
term for some other medical conditions.  
The effectiveness of opioids in long-term chronic non-malignant pain is less clear.  Ten to twenty years ago 
emerging literature led to a view that opioids may play a role in long-term pain.  New opioid products and 
preparations were brought to the market with this in mind.  While the evidence did not stretch into the long-
term, it was recognised that it would be very difficult to undertake such long-term trials.  Nevertheless, there 
was a strong clinical view that opioids were helpful in some patients not treatable by other methods which was 
logical given their known physiology.
Key Messages:
There is an urgent need to:-
Screen and assess people on opioids, 
Make clinical decisions about opioid reduction and optimal pain management where appropriate, 
Identify the best clinical approach and place (GP surgery, hospital clinic, community pharmacy) for 
this to occur, 
Ensure that there are resources to deal with those patients captured by any
screening process,
  Employ a corporate approach to manage those who are non-compliant (see   ‘Recommended Ac-
tions’).
This should be proactively linked to interdisciplinary pain assessment and management to ensure best 
pain management through other strategies and treatments.
The required services need to be fully commissioned to support patients.
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2Dose of opioids for chronic non-malignant pain
A major problem at the time opioids began to be used for chronic pain was that there was an absence of 
guidance or direction about which opioids to use and to what dose.  
The current view of the Faculty of Pain Medicine is that opioids do work for chronic pain in selected patients 
as part of a comprehensive pain management plan. They should be used in low doses with close monitoring 
of clinical effect. Dose escalation suggests that the pain is probably not opioid-responsive and the dose should 
be tapered down. Doses above 120mg morphine equivalence per day should be considered high dose and are 
associated with increasing risks to the patient. This might change as new information becomes available. Best 
practice is to keep the opioid dose as low as possible and the balance of dose-related risks and benefits should 
be actively reviewed.  
History: Why we are where we are
Chronic pain has proven to be complex to assess, evaluate and manage. There is a lack of pain training at 
both undergraduate and postgraduate level yet most patients continue to be seen by doctors other than 
pain specialists. Lack of understanding that pain can be a disease in its own right rather than a symptom and 
incorrect use of the WHO analgesic ladder has sometimes led to premature or inappropriate initiation of 
opioids.
To confound matters, when strong opioids began to be used for chronic pain, the experience of most medical 
practitioners for using opioids in the longer term related to their use in palliative care. In cancer patients, 
very high doses of opioid would be commonplace together with the use of high doses for breakthrough pain.  
Traditionally, breakthrough doses were added to a daily maintenance dose and opioid doses would rise to 
those reported to be required for clinical effect.
To consolidate this clinical direction, many patients have strong views that opioids are helpful.  They describe 
their pain as worse when medicines are reduced or omitted.  However, it is concerning that many of these 
patients still describe having very high levels of pain, distress and disability. It is important to state that the 
majority take medicines as prescribed without evidence of misuse but at doses that have higher risks.  A 
further problem is that, if opioids are used by patients more frequently or at higher doses than originally 
prescribed as occasionally happens due to limited responsiveness, the situation becomes increasingly difficult 
to manage. If further opioids are not prescribed to fill the inevitable gap when the current opioid prescription 
has been exhausted at an earlier point, then acute withdrawal might occur meaning GPs are caught between 
a rock and a hard place, a process that can lead to further escalation even when the aim was to reduce them. 
This driver for overuse of opioids is not recreational use but poorly controlled pain.
USA vs. UK
Recently there have been very significant public health concerns in America regarding opioid related deaths. 
Alarm has been transferred across to Europe. The position in the United Kingdom is different due to the 
different healthcare structures and particularly with individuals registered with one General Practitioner.
However, there is a growing concern about the increase in use of opioid painkillers in the UK and whether 
this is clinically justified. Increase in opioid prescription could be attributed to an improvement in the 
understanding and assessment of pain problems, but this is unlikely to be the full explanation. The Faculty of 
Pain Medicine has been concerned by reports of prescriptions of opioids at high dose that are very unlikely 
to be having clinical benefit.  In addition, it is clear that the higher the dose then the higher the risk of side 
3effects, overdose, abuse or diversion. The risks are also greater when other psychoactive medications are used, 
prescription or otherwise.  It is also increasingly clear that many patients who reach higher doses of opioids 
simply followed a pattern of escalating dose steps through recurrent tolerance with no significant effect on 
their level of pain or function.
Against this backdrop, public understanding of this issue is complicated by competing lobbies (with both 
commercial and non-commercial interests).  One view focuses on their value while the second competing 
view focuses on harm and the notion of an opioid epidemic.  In this debate, emphasis must remain on the 
devastating impact of chronic pain on individuals causing distress, disability and leading to huge societal costs. 
The need to treat pain and provide comprehensive interdisciplinary pain services must not be overlooked. The 
careful use of opioids for chronic pain can only ever be part of a package of care. Deficiencies in the provision 
of pain services must be considered part of the problem resulting in a lack of availability of other treatments 
and an overreliance on opioids.
Opioids Aware
The negative effects of opioid drugs in certain circumstances should not be ignored but, while recognising the 
risks, it is important to avoid inappropriate knee jerk responses promoting widespread withdrawal.  Opioid 
painkillers have benefits to many patients, which are not replicated in other drugs and cannot be easily 
replaced.
The Faculty of Pain Medicine recognises the management of complex pain is not straightforward and with 
Public Health England has developed the “Opioids Aware Resource”1 for professionals and patients to enable 
the effective and safe use of opioid medications. The resource has a dedicated area for patients, which they 
can access.2 
Our greater understanding of medications can improve the quality of life for tens of thousands of patients in 
the United Kingdom living with complex pain.  However, all healthcare staff need to ensure they are not doing 
more harm than good.  
Regional variations
There is considerable variation in the prescription of opioids across the United Kingdom. Pain physicians 
believe it is imperative that we act robustly in investigating, assessing and, where necessary, acting.
Recommended Actions 
Continue practice of screening in pain units. Currently, all patients attending a Pain Unit should have their 
medicines assessed including opioid doses, and advice given.   A careful risk benefit analysis has to be 
considered because there is a risk of morbidity and mortality in reducing opioids.  Increased pain or withdrawal 
may worsen psychiatric co-morbidity.  If the patient is well established on a dose that has not escalated for 
a long period of time with improved quality of life and significant reduction in pain, any opioid dose changes 
must be tailored for the patient. For most patients, opioid reduction can be done slowly in the community, but 
General Practitioners and local pharmacies should have the facility  to work closely with support and  advice 
from specialist pain units and if necessary, jointly with addiction centres. Patients will also require support in 
reducing their does and managing their withdrawal. 
Reducing patients to safe and stable doses should always be the central aim.
1 https://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware 
2 https://www.rcoa.ac.uk/node/21133 
4Screen, triage and assess. We need to find local mechanisms through regional pharmacy and GP authorities to 
identify those patients on high dose opioid (e.g. >120mg daily morphine equivalents) and to undertake triage 
and clinical assessment to identify the correct course of action, both to manage pain and the level of opioid 
dose.
Manage non-compliance. It is recognised in this process that there are some patients who will not be 
compliant.  These patients cannot be treated without consent because they will not meet the criteria for 
legislative medical intervention.  Therefore, very careful consideration is required for patients who either do 
not attend or comply with the medical recommendations. These patients should be managed in conjunction 
with the General Practitioners to have a plan for opioid reduction.
Specialist resources. In view of the complex issues involved, best care involves collaborative working between 
community services, pain services, General Practitioners and, where necessary, addiction services with 
experience in prescription opioids. Most addiction services will not treat prescription opioids for pain. There 
are some specialist centres with opioid reduction clinics and these centres might be a useful resource for 
patients.
In addition, some highly specialist inpatient pain medication optimisation clinics will be required for opioid 
optimisation or reduction in complex cases. 
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